Mikron Group Achieves Significant Growth in Sales and Profits in 2023

Mikron Holding AG reported a notable improvement in its financial performance for the year 2023. The company saw a substantial increase in annual net sales across both its business segments, attributed to strong demand in key markets and robust growth in the Automation division. Net sales escalated by 19.7% to CHF 370.2 million, from CHF 309.4 million in the previous year. The group's EBIT surged by 33.7% to CHF 35.3 million, and the profit for the year rose by 19.0% to CHF 28.8 million.

Mikron's divisions capitalized on high demand from the pharmaceutical, medical technology, watchmaking, and writing industries. Efforts to manage rising inflation and the easing of global supply chain restrictions positively influenced sales and profitability. The Group's order intake reached CHF 412.1 million, a slight increase from the previous year's CHF 408.0 million.

Europe remained Mikron's largest market, contributing 59% to total net sales, with North America following at 25%. The pharmaceutical and medical technology sectors continued as the strongest market segment, accounting for 57% of total net sales. The Group reported a high order backlog, ending the year at CHF 304.3 million, a 12.4% increase over the prior year, indicating sustained high capacity utilization across its divisions.

Looking ahead, Mikron is cautious about the 2024 financial outlook due to global economic uncertainties. However, the Group anticipates stability in sales and a similar operating result margin to 2023, backed by a sound cost structure and solid order backlog.